Preparing for Brexit - The Quick Group Preparation Plan

23 Jan, 2019 by  James Smith

With the impending schedule for the UK to leave the European Union on 29th March 2019, the world is waiting for the outcome and ramifications of Brexit –whether a "Go" or "No-Go" decision.

In preparation for Brexit, The Quick Group formulated a team of our industry and subject matter experts to assess all possible outcomes, the impact on our customers, as well as our organization. Extensive contingency planning and preparations have been made to manage and ensure the continuity of our service and minimize supply chain risks.

Over the past two years, Quick's global footprint and service partner network has been significantly expanded, along with increased brokerage capabilities. We have hired additional regulatory, compliance and cold chain specialists throughout the world, who are focused on designing comprehensive logistics plans for all aspects of the supply chain.

To provide the smoothest transition possible for our customers, Quick’s Brexit Team has carefully reviewed options for the many components of the logistics process, including a selection of alternative transit hubs and port access, mapping out lane selections, and alternatives for importing/exporting and customs clearance.

When the Brexit decision is made, our specialists will be ready to provide consultation and assistance with the new requirements relating to the EU-UK movements of goods. They will help you plan your clinical supply chain, providing safe and timely transit of biological specimens, clinical supplies, packaging solutions, investigative drugs, and personalized medicine.

Impact on The Pharma & Biotech Industry

While this decision will impact all of commerce, Brexit will have a significant impact on the pharmaceutical and biotech industry supply chain, where the development of drugs and other products depend heavily on the political and regulatory conditions of a country, and often require planning years in advance. In case of a no-deal decision, the possible consequences would be:

  • The UK will exit the EU and will also exit the EU Customs Union, all material transfer between UK & EU will be subject to customs and WTO (World Trade Organization) customs tariff
  • Goods transferred from the UK to EU will be considered as a 3rd country rule, e.g., Licensing requirements for transfer of animal products & by-products
  • The UK will no longer be used as a hub for transfer from diagnostic specimens from EU to the US; exports would need to be performed from EU Hubs
  • Reusable packaging provisioned from the UK to the EU would be subject to customs clearance and VAT/duty payments, resulting in possible supply chain delays and associated costs

Our logistics experts are available 24/7 to answer your questions and provide consultation on all aspects of your clinical supply chain.

About James Smith
Global Operations Director

James Smith has been with the Quick Group of Companies for over 9 years in various management positions, and currently holds the position of Global Operations Director.

With over 15 years in life science logistics,... Read more.

Recent Blog Posts: